Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
2000 Turkeys
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
2000 Turkeys
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
132.81
-4.97 (-3.61%)
Official Closing Price
Updated: 6:30 PM EST, Nov 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop
October 30, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline
October 30, 2026
From
The Law Offices of Howard G. Smith
Via
Business Wire
Merck & Co., Inc. Q3 Earnings Call Highlights
↗
October 30, 2026
Merck & Co., Inc. (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines, cardiometabolic products and animal health helped offset...
Via
MarketBeat
Topics
Earnings
Merck & Co. (NYSE:MRK) Posts Q3 Earnings Beat as EPS Surprise Offsets In-Line Sales Guidance
↗
October 29, 2026
Via
Chartmill
Topics
Earnings
Dow Jones Top Gainers in Today's Session: 3M Leads
↗
October 20, 2026
Via
Chartmill
Topics
Stocks
Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 1.76% Stock Decline
October 29, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Dow Jones Top Movers for Oct. 29, 2026: Merck and Nike Lead Gainers, Alphabet and Caterpillar Fall
↗
October 29, 2026
Via
Chartmill
Topics
Stocks
Merck (MRK) Q3 2026 Earnings Call Transcript
↗
October 29, 2026
Generic headwinds ahead in 2027, but new launches and WINREVAIR growth signal momentum.
Via
The Motley Fool
Topics
Earnings
Dow Jones Top Gainers on Oct. 20, 2026: MMM, UNH, MRK Lead Session
↗
October 20, 2026
Via
Chartmill
Topics
Stocks
Merck (NYSE:MRK) Nears Breakout Setup With Strong Technical Ratings
↗
October 20, 2026
Via
Chartmill
Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction
↗
October 29, 2026
Merck’s new drugs are growing fast enough to cover generic losses, but part of this quarter’s sales gain won’t last. Here’s what to watch.
Via
The Motley Fool
Topics
Intellectual Property
Dow Jones Top Movers Today: 8 Gainers, 4 Losers in Split Session
↗
October 29, 2026
Via
Chartmill
Topics
Stocks
Merck (NYSE:MRK) delivers impressive Q3 2026
October 29, 2026
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q3 2026, with revenue rising 4.7% year on year to $18.09 billion. Th...
Via
StockStory
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
October 29, 2026
From
Merck & Co., Inc.
Via
Business Wire
Could Revolution Medicines Be a Millionaire-Maker Stock?
↗
October 29, 2026
The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one.
Via
The Motley Fool
Merck (MRK) reports Q3: everything you need to know ahead of earnings
October 27, 2026
Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday before market open. Here’s what investors should know. Merck beat ana...
Via
StockStory
Topics
Artificial Intelligence
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
↗
October 27, 2026
Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.
Via
MarketBeat
Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts
↗
October 26, 2026
Merck & Co., Inc. (NYSE:MRK) outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab...
Via
MarketBeat
S&P 500 Top Movers: Gainers and Losers in Today's US Session
↗
October 26, 2026
Via
Chartmill
Topics
Stocks
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
↗
October 26, 2026
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.
Via
MarketBeat
Topics
Artificial Intelligence
KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
October 26, 2026
From
Merck & Co., Inc.
Via
Business Wire
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
October 26, 2026
From
Merck & Co., Inc.
Via
Business Wire
A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets
October 26, 2026
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.
From
Biotech Insider
Via
GlobeNewswire
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach
↗
October 23, 2026
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.
Via
MarketBeat
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
October 22, 2026
From
Merck & Co., Inc.
Via
Business Wire
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
October 21, 2026
Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.
From
FN Media
Via
GlobeNewswire
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
October 21, 2026
EQNX::TICKER_START (NASDAQ:NTHI),(NASDAQ:NBIX),(NASDAQ:ACAD),(NASDAQ:AVXL),(NYSE:MRK) EQNX::TICKER_END
Via
FinancialNewsMedia
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026
↗
October 21, 2026
The market has rewarded this biotech for its breakthroughs.
Via
The Motley Fool
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
October 21, 2026
From
Merck & Co., Inc.
Via
Business Wire
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice
↗
October 21, 2026
This company made headlines with its coronavirus vaccine.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today